Tudor Investment Corp ET AL Has $2.75 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Tudor Investment Corp ET AL decreased its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 458,488 shares of the company's stock after selling 57,284 shares during the quarter. Tudor Investment Corp ET AL owned 0.31% of Adaptive Biotechnologies worth $2,749,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ADPT. Susquehanna Fundamental Investments LLC acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $226,000. Voya Investment Management LLC raised its stake in Adaptive Biotechnologies by 6,121.7% during the 4th quarter. Voya Investment Management LLC now owns 2,428,710 shares of the company's stock worth $14,560,000 after acquiring an additional 2,389,674 shares in the last quarter. Dark Forest Capital Management LP purchased a new stake in Adaptive Biotechnologies in the fourth quarter valued at $310,000. Hsbc Holdings PLC boosted its stake in Adaptive Biotechnologies by 30.9% in the fourth quarter. Hsbc Holdings PLC now owns 47,276 shares of the company's stock valued at $289,000 after acquiring an additional 11,165 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Adaptive Biotechnologies by 5.6% in the 4th quarter. MetLife Investment Management LLC now owns 68,976 shares of the company's stock valued at $414,000 after purchasing an additional 3,650 shares during the period. Hedge funds and other institutional investors own 99.17% of the company's stock.

Adaptive Biotechnologies Trading Up 4.0 %

ADPT traded up $0.35 during trading on Thursday, reaching $9.16. 514,215 shares of the company were exchanged, compared to its average volume of 1,584,321. Adaptive Biotechnologies Co. has a 52 week low of $2.99 and a 52 week high of $10.28. The firm has a 50 day moving average of $7.82 and a 200 day moving average of $6.98. The stock has a market cap of $1.39 billion, a P/E ratio of -8.40 and a beta of 1.75.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The company had revenue of $52.44 million for the quarter, compared to analyst estimates of $42.13 million. During the same quarter last year, the business earned ($0.33) earnings per share. Adaptive Biotechnologies's revenue was up 25.2% compared to the same quarter last year. As a group, analysts forecast that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ADPT shares. Scotiabank raised their price target on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. The Goldman Sachs Group boosted their target price on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and issued a $13.00 price objective (up previously from $11.00) on shares of Adaptive Biotechnologies in a research note on Tuesday. Finally, Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $9.83.

Insider Buying and Selling

In other news, Director Peter M. Neupert sold 10,000 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.05, for a total transaction of $70,500.00. Following the completion of the sale, the director now directly owns 224,690 shares of the company's stock, valued at $1,584,064.50. This trade represents a 4.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Harlan S. Robins sold 68,412 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $7.35, for a total transaction of $502,828.20. Following the completion of the sale, the insider now owns 1,279,524 shares of the company's stock, valued at $9,404,501.40. This represents a 5.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 826,013 shares of company stock worth $6,543,452 in the last ninety days. 6.20% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.